Dermatomyositis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Dermatomyositis Market Outlook
Thelansis’s “Dermatomyositis Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Dermatomyositis treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Dermatomyositis
Overview
Dermatomyositis
(DM) is an idiopathic inflammatory myopathy multisystem disorder characterized
by progressive, symmetrical proximal muscle weakness and pathognomonic or
characteristic cutaneous manifestations. In some patients with DM, cutaneous
disease exists in the absence of objective evidence of muscle inflammation, and
these cases are referred to as amyopathic DM. The myopathy primarily affects
the proximal muscles, is usually symmetrical, and is slowly progressive over
weeks to months. Initial complaints include myalgias, fatigue, or weakness
manifested as an inability to climb stairs, raise the arms for actions like
hair grooming or shaving, rise from a squatting or sitting position, or a
combination of these features. Arthralgias and arthritis may be present in up
to one-fourth of patients with inflammatory myopathy. As manifested by
dysphagia, the esophagal disease is estimated to be present in 15% to 50% of
patients with inflammatory myopathy. The pulmonary disease occurs in DM and PM
in approximately 15% to 65% of patients. Interstitial pneumonitis is a primary
process observed in DM/PM.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment